Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$43.50 USD
-1.22 (-2.73%)
Updated May 6, 2024 04:00 PM ET
After-Market: $43.49 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNDM 43.50 -1.22(-2.73%)
Will TNDM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNDM
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
Tandem Diabetes Care (TNDM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
Other News for TNDM
Tandem Diabetes price target raised by $16 at Barclays, here's why
DexCom: Attractive Discount After Strong Earnings Results
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)
Nasdaq Surges 2%; Apple Posts Upbeat Results
12 Health Care Stocks Moving In Friday's Intraday Session